Table 1.

Patient demographics, primary diagnosis, antiviral prophylaxis, death rate, and graft failure rate by number of CMV viremia episodes.

Number of episodes	0 (n = 2,030)	1 (n = 367)	2+ (n = 67)	P-value***
Sex, n (%)
Male	1,279 (63.0)	224 (61.0)	42 (62.7)	0.7728
Female	751 (37.0)	143 (39.0)	25 (37.3)
Age <19 years, n (%)*
Yes	71 (3.5)	3 (0.8)	1 (1.5)	0.7728
No	1,959 (96.5)	364 (99.2)	66 (98.5)
Age, years*
Minimum	1.7	6.6	16.6	0.0000
Median	53.2	58.4	60
Maximum	81.1	82	77.6
Standard deviation	15.3	14.5	12.3
Mean	51.1	55.1	58.2
Mean 95% CI	(50.4, 51.7)	(53.6, 56.6)	(55.2, 61.2)
Race, n (%)
Caucasian/White	1,246 (61.4)	193 (52.6)	33 (49.3)	0.0014
Other	784 (38.6)	174 (47.4)	34 (50.8)
CMV D/R status at baseline, n (%)
D-/R-	438 (21.6)	2 (0.5)	2 (3.0)	0.0000
D-/R+	600 (29.6)	75 (20.4)	10 (14.9)
D+/R-	299 (14.7)	125 (34.1)	30 (44.8)
D+/R+	693 (34.1)	165 (45.0)	25 (37.3)
Primary diagnosis, n (%)
Glomerulonephritis	710 (35.0)	98 (26.7)	20 (29.9)	0.0206
Diabetes	450 (22.2)	93 (25.3)	12 (17.9)
Other	870 (42.9)	176 (48.0)	35 (52.2)
Prophylaxis, n (%)**
Yes	829 (40.8)	242 (65.9)	52 (77.6)	0.0000
No	1,201 (59.2)	125 (34.1)	15 (22.4)
Duration of prophylaxis, days**
Minimum	2.0	2.0	3.0	0.0560
Median	78.0	94.5	104.0
Maximum	867.0	596.0	1638.0
Standard deviation	88.3	98.2	244.4
Mean	101.4	119.2	154.0
Mean 95% CI	(95.3, 107.4)	(106.7, 131.6)	(86.0, 222.0)
Death, n (%)
Survived	1,815 (89.4)	322 (87.7)	48 (71.6)	0.0000
Died	215 (10.6)	45 (12.3)	19 (28.4)
Graft failed, n (%)
No	1,896 (93.4)	336 (91.6)	55 (82.1)	0.0012
Yes	134 (6.6)	31 (8.5)	12 (17.9)

*Age at first transplantation.

**Prophylaxis refers to any administration of CMV treatment drugs within first 14 days post-transplant.

***P-value for comparison by number of CMV viremia episodes.

CI, confidence interval; CMV, cytomegalovirus; D, donor; R, recipient.